Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | TDP2 | O95551 | 2/20 | 0.42 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | S100A4 | P26447 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30285264 | 1.00 | PARP10 (0.50) | PARP10PARP1TDP2PARP11TGM2 | |
| SCHEMBL12078131 | 0.87 | TDP2 (0.46) | PARP10PARP1TDP2PARP11TGM2 | |
| SCHEMBL428211 | 0.81 | PARP10 (0.51) | PARP10PARP1PARP11CDC7MEN1 | |
| SCHEMBL23865208 | 0.80 | PARP10 (0.50) | PARP10PARP1TDP2PARP11TGM2 | |
| SCHEMBL21351074 | 0.80 | PARP10 (0.50) | PARP10PARP1TDP2PARP11TGM2 | |
| SCHEMBL445602 | 0.80 | CDC7 (0.43) | PARP1TDP2CDC7MEN1KMT2A | |
| SCHEMBL24510632 | 0.78 | PARP10 (0.47) | PARP10PARP1TDP2PARP11TGM2 | |
| SCHEMBL24509680 | 0.78 | PARP10 (0.47) | PARP10PARP1TDP2PARP11TGM2 | |
| SCHEMBL24509888 | 0.76 | PARP10 (0.46) | PARP10PARP1TDP2PARP11TGM2 | |
| SCHEMBL445340 | 0.76 | CYP3A4 (0.53) | TDP2CES1MEN1KMT2AS100A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111825656-B | Inhibitors of protein arginine methyltransferase 5 (PRMT 5), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11591326-B2 | Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2023-02-28 | — | — | US | disclosed |
| EP-3761978-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2021-01-13 | — | — | EP | disclosed |
| US-20200399261-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2020-12-24 | — | — | US | disclosed |
| US-20200399261-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2020-12-24 | — | — | US | disclosed |
| CN-111825656-A | Inhibitors of protein arginine methyltransferase 5(PRMT5), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2020-10-27 | — | — | CN | disclosed |
| WO-2019173804-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019173804-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591326-B2 | Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof | PRMT5, PRMT1, PRMT3 | PARP10 120/4885PARP1 351/4885TDP2 2520/4885 |
| US-20200399261-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PRMT5, PRMT1, PRMT3 | PARP10 120/4885PARP1 351/4885TDP2 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.